This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Levy, B. D. Search for Related Content PubMed PubMed Citation Articles by Levy, B. D. Related Collections Biochemistry and metabolism Animal models of human disease Other Treatment Lipid and lipoprotein metabolism

(Circulation. 2006;114:873-875.)
© 2006 American Heart Association, Inc.

Editorial

Myocardial 15-Epi-lipoxin A₄ Generation Provides a New Mechanism for the Immunomodulatory Effects of Statins and Thiazolidinediones

Bruce D. Levy, MD

From the Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, Brigham and Women’s Hospital, Boston, Mass.

Correspondence to Bruce D. Levy, MD, Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail blevy@partners.org

Key Words: Editorials • drugs • fatty acids • hydroxymethylglutaryl-CoA reductase inhibitors • inflammation • lipids • myocardium

An extract of the first 250 words of the full text is provided, because this article has no abstract.

"In matters of observation, chance favors only the prepared mind."

This famous maxim of Louis Pasteur, spoken in 1854 during his inaugural lecture as Professor and Dean at the University of Lille, can be applied today to the fortuitous observation that hydroxymethylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors, in addition to their designed lipid-lowering effects, display a fascinating array of antiinflammatory properties. Post hoc analyses of the West of Scotland Coronary Prevention Study (WOSCOPS) population, and more recently the Cholesterol and Recurrent Events (CARE), Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL), Long-term Intervention With Pravastatin in Ischemic Disease (LIPID), and Heart Protection Study (HPS) trials, have all found benefits conferred by statins that are independent of low-density lipoprotein cholesterol–lowering alone.¹ Only through careful analyses of early clinical trials of statins administered for lowering cholesterol and cardiovascular events did scientists uncover additional benefit for these agents in cardiac protection beyond their ability to reduce cholesterol synthesis. Inflammation and immune responses are now appreciated to play pivotal roles in the pathobiology of atherosclerosis,² and recent clinical and basic investigations have uncovered important immunomodulatory roles for statins.³ Of interest, the peroxisome proliferator-activated receptor family of transcription factors is activated by and cooperates with statins in their antiinflammatory actions. In this issue of Circulation, Birnbaum and colleagues⁴ present evidence for increased myocardial production of 15-epi-lipoxin (LX)A₄ by atorvastatin and the peroxisome proliferator-activated receptor- ligand pioglitazone. The generation of 15-epi-LXA₄ would provide a novel mechanism for immune regulation by statins because this arachidonic acid–derived chalone . . . [Full Text of this Article]